Sol-Gel Technologies Pre-Tax Profit Margin 2016-2024 | SLGL
Sol-Gel Technologies pre-tax profit margin from 2016 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Sol-Gel Technologies Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2024-12-31 |
$0.01B |
$-0.01B |
-100.00% |
| 2024-09-30 |
$0.01B |
$-0.01B |
-90.00% |
| 2024-06-30 |
$0.01B |
$-0.02B |
-300.00% |
| 2024-03-31 |
$0.00B |
$-0.02B |
-2300.00% |
| 2023-12-31 |
$0.00B |
$-0.03B |
-2800.00% |
| 2023-09-30 |
$0.00B |
$-0.03B |
-2900.00% |
| 2023-06-30 |
$0.00B |
$-0.03B |
-2600.00% |
| 2023-03-31 |
$0.00B |
$-0.02B |
-500.00% |
| 2022-12-31 |
$0.00B |
$-0.02B |
-375.00% |
| 2022-09-30 |
$0.03B |
$0.01B |
20.00% |
| 2022-06-30 |
$0.03B |
$0.01B |
26.47% |
| 2022-03-31 |
$0.03B |
$0.00B |
3.23% |
| 2021-12-31 |
$0.03B |
$0.00B |
9.38% |
| 2021-09-30 |
$0.01B |
$-0.02B |
-130.77% |
| 2021-06-30 |
$0.01B |
$-0.03B |
-450.00% |
| 2021-03-31 |
$0.01B |
$-0.03B |
-433.33% |
| 2020-12-31 |
$0.01B |
$-0.03B |
-362.50% |
| 2020-09-30 |
$0.01B |
$-0.03B |
-300.00% |
| 2020-06-30 |
$0.01B |
$-0.03B |
-215.38% |
| 2020-03-31 |
$0.02B |
$-0.03B |
-130.00% |
| 2019-12-31 |
$0.02B |
$-0.03B |
-108.70% |
| 2019-09-30 |
$0.02B |
$-0.03B |
-163.16% |
| 2019-06-30 |
$0.01B |
$-0.03B |
-228.57% |
| 2019-03-31 |
$0.01B |
$-0.03B |
-566.67% |
| 2018-12-31 |
$0.00B |
$-0.03B |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.021B |
$0.012B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
